DE-IDENTIFIED HEALTH DATA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

De-identified Health Data Market, By Type of Data (Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data , Laboratory Data, Social Determinants of Health (SDOH) Data, and Others), By Application (Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, and Others), By End User (Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Insurance Companies/Healthcare Payers, Research Institutions, Government Agencies, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Nov 2024
Code : CMI7476
Pages :135
Formats :
Excel and PDF
Industry : Healthcare IT

De-identified Health Data Market Size and Trends

De-identified health data market is estimated to be valued at USD 7.51 Bn in 2024 and is expected to reach USD 13.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. With increasing focus on data privacy and availability of large amounts of healthcare data, de-identified health data market is expected to witness rapid growth in the near future.

De-identified Health Data Market Key Factors

To learn more about this report, request sample copy

Rising demand for real-world evidence and integration of analytics in healthcare are also driving the market growth. Furthermore, increasing investments by pharmaceutical and medical devices companies in digital healthcare will boost the need for anonymized healthcare databases.

Top Strategies Followed by De-identified Health Data Market Players

Established players in the global de-identified health data industry emphasize research and development to maintain a competitive edge. For example, in May 2020, IBM announced plans to invest over USD 6 billion annually to advance artificial intelligence and cloud technologies, enabling organizations to extract valuable insights from health data. IBM also forms strategic partnerships in areas like telehealth and genomics, enhancing its capability to offer comprehensive data-driven healthcare solutions.
Mid-sized companies focus on niche specialization and cost-effective offerings, targeting specific therapeutic areas or regional health systems with tailored products and services priced affordably to meet localized needs.
Small startups adopt a grassroots approach, often concentrating on specific segments within the de-identified data space. Some startups develop innovative methods to analyze socioeconomic data, while others focus on extracting insights from medical imagery. By addressing these narrow needs, they gain specialized expertise and create unique solutions.

Emerging Startups in the De-identified Health Data Market

Emerging startups in the de-identified health data industry are leveraging advanced technologies to enhance patient privacy while enabling data sharing for research and analytics. For instance, Orion Health announced advancements in its end-to-end de-identification software in January 2023, ensuring compliance with regulations like HIPAA and focusing on both structured and unstructured data.
Shaip detailed its automated solutions for anonymizing sensitive health information in March 2023. Skyflow uses techniques such as tokenization and polymorphic encryption to safeguard patient data, with significant discussions about its innovations occurring throughout 2023, particularly emphasized in February 2023. These developments highlight the dynamic nature of the de-identified health data sector and its commitment to privacy and security.